Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy

Human Gene Therapy

Volumn 23, Issue 3, 2012, Pages 295-301

  Li, Hongtao ^a   Peng, Kah Whye ^a   Russell, Stephen J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IODINE 131; ONCOLYTIC VIRUS; SODIUM IODIDE SYMPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; GENETIC CODE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; MEASLES VIRUS; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; RADIOIODINATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; TUMOR CELL; VIRUS GENE; XENOGRAFT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, INTRALESIONAL; IODINE RADIOISOTOPES; MEASLES VIRUS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SYMPORTERS; TRANSPLANTATION, HETEROLOGOUS;

MEASLES VIRUS;

EID: 84863239353     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.128     Document Type: Article

References (33)

1. Anderson, B.D., Nakamura, T., Russell, S.J., and Peng, K.W. (2004). High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 64, 4919-4926. (Pubitemid 38924538)
2. Ayllón Barbellido, S., Campo Trapero, J., Cano Sánchez, J., et al. (2008). Gene therapy in the management of oral cancer: review of the literature. Med. Oral Patol. Oral Cir. Bucal 13, E15-E21. (Pubitemid 351154783)
3. Barton, K.N., Stricker, H., Brown, S.L., et al. (2008). Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol. Ther. 16, 1761-1769.
4. Blanchard, P., Hill, C., Guihenneuc-Jouyaux, C., et al. (2011). Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. J. Clin. Epidemiol. 64, 985-992.
5. Bushnell, D.L., Boles, M.A., Kaufman, G.E., et al. (1992). Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma. J. Nucl. Med. 33, 2214-2221.
6. Chin, D., Boyle, G.M., Porceddu, S., et al. (2006). Head and neck cancer: past, present and future. Expert Rev. Anticancer Ther. 6, 1111-1118. (Pubitemid 44203388)
7. Currier, M.A., Gillespie, R.A., Sawtell, N.M., et al. (2008). Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol. Ther. 16, 879-885. (Pubitemid 351587097)
8. Dadachova, E., and Carrasco, N. (2004). The Na/I symporter (NIS): imaging and therapeutic applications. Semin. Nucl. Med. 34, 23-31. (Pubitemid 38056401)
9. Dai, G., Levy, O., and Carrasco, N. (1996). Cloning and characterization of the thyroid iodide transporter. Nature 379, 458-460. (Pubitemid 26039527)
10. Dingli, D., Peng, K.W., Harvey, M.E., et al. (2004). Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103, 1641-1646. (Pubitemid 38268954)
11. Galanis, E., Okuno, S.H., Nascimento, A.G., et al. (2005). Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 12, 437-445. (Pubitemid 40394296)
12. Garber, K. (2006). China approves world's first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 98, 298-300.
13. Harrington, K.J., Hingorani, M., Tanay, M.A., et al. (2010). Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin. Cancer Res. 16, 4005-4015.
14. Hasegawa, K., Pham, L., O'Connor, M.K., et al. (2006). Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin. Cancer Res. 12, 1868-1875.
15. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. CA Cancer J Clin. 60, 277-300.
16. Langfield, K.K., Walker, H.J., Gregory, L.C., and Federspiel, M.J. (2011). Manufacture of measles viruses. Methods Mol. Biol. 737, 345-366.
17. Lefebvre, J.L. (2005). Current clinical outcomes demand new treatment options for SCCHN. Ann. Oncol. 16 Suppl 6, vi7-vi12.
18. Li, H., Peng, K.W., Dingli, D., et al. (2010). Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther. 17, 550-558.
19. Liu, C., Sarkaria, J.N., Petell, C.A., et al. (2007). Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin. Cancer Res. 13, 7155-7165. (Pubitemid 350276902)
20. Liu, T.C., and Kirn, D. (2008). Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther. 15, 877-884. (Pubitemid 351791475)
21. Liu, T.C., Galanis, E., and Kirn, D. (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4, 101-117. (Pubitemid 46189539)
22. Mace, A.T., Ganly, I., Soutar, D.S., and Brown, S.M. (2008). Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck 30, 1045-1051.
23. Morganti, A.G., Mignogna, S., Deodato, F., et al. (2011). Feasibility study of moderately accelerated intensity-modulated radiotherapy plus concurrent weekly cisplatin after induction chemotherapy in locally advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 79, 1073-1080.
24. Myers, R.M., Greiner, S.M., Harvey, M.E., et al. (2007). Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin. Pharmacol. Ther. 82, 700-710. (Pubitemid 350114828)
25. Nguyen, T.L., Tumilasci, V.F., Singhroy, D., et al. (2009). The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies. Cell. Microbiol. 11, 889-897.
26. Penheiter, A.R., Wegman, T.R., Classic, K.L., et al. (2010). Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. AJR Am. J. Roentgenol. 195, 341-349.
27. Penheiter, A.R., Griesmann, G.E., Federspiel, M.J., et al. (2011). Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. Gene Ther. [Epub ahead of print]
28. Russell, S.J., and Peng, K.W. (2007). Viruses as anticancer drugs. Trends Pharmacol. Sci. 28, 326-333. (Pubitemid 47016683)
29. Russell, S.J., and Peng, K.W. (2008). The utility of cells as vehicles for oncolytic virus therapies. Curr. Opin. Mol. Ther. 10, 380-386.
30. Sankaranarayanan, R., Masuyer, E., Swaminathan, R., et al. (1998). Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res. 18, 4779-4786. (Pubitemid 29042060)
31. Sisson, J.C., and Carey, J.E. (2001). Thyroid carcinoma with high levels of function: treatment with 131I. J. Nucl. Med. 42, 975-983. (Pubitemid 32537448)
32. Tyminski, E., Leroy, S., Terada, K., et al. (2005). Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res. 65, 6850-6857. (Pubitemid 41060724)
33. Zuckier, L.S., Dohan, O., Li, Y., et al. (2004). Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. J. Nucl. Med. 45, 500-507. (Pubitemid 47618627)